Ista sees 2007 gross margin of 70-74 percent
April 26 (Reuters) - Ista Pharmaceuticals Inc. (ISTA.O) on Thursday said it expects its 2007 gross margin of 70 to 74 percent.
In a conference call, the ophthalmic pharmaceutical company said it continues to expect 2007 research and development expense of $24 million to $28 million. (Reporting by Niveditha Ravi in Bangalore)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
